Two new studies found that a new, investigational colorectal cancer screening test developed by the Mayo Clinic and Exact Sciences of Madison, Wis., is accurate and more sensitive than other noninvasive tests at detecting adenomas and early-stage cancer, according to a Mayo Clinic blog post.
The stool DNA testing finds signature genetic markers in stool samples patients collect at home and mail in to labs. The first study will be published in the February issue of Gastroenterology, and the second will be published in the March issue of Clinical Gastroenterology and Hepatology.
Related Articles on Colorectal Cancer:
Bayer Seeks FDA Approval for First New Drug to Treat Colorectal Cancer in 5 Years
The Colon Cancer Screening Controversy: How Old is Too Old to Screen?
Gene Mutation Linked to Chemo-Resistant Colon Cancer
The stool DNA testing finds signature genetic markers in stool samples patients collect at home and mail in to labs. The first study will be published in the February issue of Gastroenterology, and the second will be published in the March issue of Clinical Gastroenterology and Hepatology.
Related Articles on Colorectal Cancer:
Bayer Seeks FDA Approval for First New Drug to Treat Colorectal Cancer in 5 Years
The Colon Cancer Screening Controversy: How Old is Too Old to Screen?
Gene Mutation Linked to Chemo-Resistant Colon Cancer